Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07037433 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
A Phase 3 study of Obesity and Overweight, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 12,800
- Enrollment target
- 20
- Study locations
NCT07037433: Recruiting Phase 3 study of Obesity and Overweight, sponsored by Amgen.
NCT07037433 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Amgen. The registered enrollment target is 12,800 participants, above the 807-participant average among 1,053 other Obesity trials with a reported enrollment target (1486% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07037433, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 12,800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maridebart Cafraglutide
Study Locations (20)
California
- Valley Clinical Trials, LLC dba Flourish Research - Covina
- Velocity Clinical Research- Huntington Park - Huntington Park
- Velocity Clinical Research- Los Angeles - La Mesa
- Orange County Research Center - Lake Forest
- Biopharma Informatic - The Cardiovascular Center - Redding
- Encompass Clinical Research - Spring Valley
- Diablo Clinical Research - Walnut Creek
- Focus Clinical Research - West Hills
Alabama
- Alliance For Multispecialty Research - Daphne - Daphne
- Eastern Shore Research Institute - Fairhope
- Heart Center Research LLC - Huntsville
- Mobile Heart Specialists PC - Mobile
- Syed Research Consultants LLC - Sheffield
Florida
- Excel Medical Clinical Trials - Boca Raton
- Velocity Clinical Research - New Smyrna Beach - Edgewater
- Alliance for Multispecialty Research - Fort Myers - Fort Myers
- Indago Research and Health Center - Hialeah
Arizona
- Synexus Clinical Research US, Inc. - Phoenix
- Medical Advancement Centers of Arizona - Phoenix
Delaware
- Family Practice Associates - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,800 participants |
| Start Date | 2025-07-25 |
| Est. Completion | 2030-09-29 |
| Phase | Phase 3 |
What NCT07037433 shows while recruiting
NCT07037433 is an interventional study that assigns participants to a tested intervention. Its 12,800 participants enrollment target places it among the larger protocols in the corpus, above the 807-participant average among 1,053 other Obesity trials with a reported enrollment target (1486% higher).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07037433 names 20 study sites across 5 states, led by California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT07037433 about?
NCT07037433 is a clinical study titled "Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity". The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
What is the current status of trial NCT07037433?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 12,800 participants. The study started on 2025-07-25. Estimated completion is 2030-09-29.
What conditions does trial NCT07037433 study?
This clinical trial studies the following conditions: Obesity, Overweight, Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT07037433?
The interventions under investigation include: Placebo (DRUG), Maridebart Cafraglutide (DRUG).
Who is sponsoring clinical trial NCT07037433?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07037433 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07037433's enrollment target sits among peer trials
12,800 6th of 1053 higher than 1,048 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03586895 · 12,838 participants · NA
e-Connect: A Service System Intervention for Justice Youth at Risk for Suicide
- NCT07028398 · 12,990 participants · NA
CMSL Ambulatory Sensitive Condition Nudge Study 2
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
- NCT07177352 · 13,000 participants · Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI